The French Competition Authority fines a pharmaceutical laboratory for abuse of dominance in denigrating its competitors and in implementing anticompetitive agreements with its suppliera (Arrow / Schering-Plough)

Press Release published on the official website of the French Competition Authority.

The Autorité de la concurrence fines the Schering-Plough pharmaceutical laboratory a total of 15.3 million euro for hindering entry onto the market of the generic of its originator medicinal product Subutex®* Following a complaint filed by the Arrow génériques laboratory, The Autorité de la concurrence has imposed a 15.3 million euro fine on the Schering-Plough laboratory for disparagement of the generic by the Arrow laboratory which is in competition with its originator medicinal product Subutex®, and for granting unwarranted discounts to pharmacists in order to curb the entry of the generic product. The Autorité has also fined an anticompetitive agreement between Schering-Plough and its supplier Reckitt Benckiser, which purpose was to implement a strategy of closing off competitors.

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

French Competition Authority, The French Competition Authority fines a pharmaceutical laboratory for abuse of dominance in denigrating its competitors and in implementing anticompetitive agreements with its suppliera (Arrow / Schering-Plough), 18 December 2013, e-Competitions Bulletin Competition in the Pharmaceutical sector, Art. N° 66210

Visites 175

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues